| Literature DB >> 32846959 |
Agnieszka Bojko1, Karolina Staniak1, Joanna Czarnecka-Herok1, Piotr Sunderland1, Magdalena Dudkowska1, Małgorzata Alicja Śliwińska2, Kristine Salmina3, Ewa Sikora1.
Abstract
The induction of senescence/polyploidization and their role in cancer recurrence is still a poorly explored issue. We showed that MDA-MB-231 and MCF-7 breast cancer cells underwent reversible senescence/polyploidization upon pulse treatment with doxorubicin (dox). Subsequently, senescent/polyploid cells produced progeny (escapers) that possessed the same amount of DNA as parental cells. In a dox-induced senescence/polyploidization state, the accumulation of autophagy protein markers, such as LC3B II and p62/SQSTM1, was observed. However, the senescent cells were characterized by a very low rate of new autophagosome formation and degradation, estimated by autophagic index. In contrast to senescent cells, escapers had a substantially increased autophagic index and transcription factor EB activation, but a decreased level of an autophagy inhibitor, Rubicon, and autophagic vesicles with non-degraded cargo. These results strongly suggested that autophagy in escapers was improved, especially in MDA-MB-231 cells. The escapers of both cell lines were also susceptible to dox-induced senescence. However, MDA-MB-231 cells which escaped from senescence were characterized by a lower number of γH2AX foci and a different pattern of interleukin synthesis than senescent cells. Thus, our studies showed that breast cancer cells can undergo senescence uncoupled from autophagy status, but autophagic flux resumption may be indispensable in cancer cell escape from senescence/polyploidy.Entities:
Keywords: DNA damage; Rubicon; SQSTM1/p62; TFEB; autophagic index; autophagy; cancer; polyploidy; senescence; senescence escape
Mesh:
Substances:
Year: 2020 PMID: 32846959 PMCID: PMC7504443 DOI: 10.3390/ijms21176084
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Markers of senescence in dox-treated MDA-MB-231 cells. Cells were treated with 100 nM doxorubicin for 24 h, then cultured in a fresh medium and analyzed on subsequent days. (a) Immunocytochemical staining visualized the activity of SA-β-gal (cells stained blue), the accumulation of lipofuscin detected by SenTraGor (cells stained brown) and the accumulation of neutral lipids detected by Oil Red O (red lipid droplets within the cytoplasm). Scale bar: 50 μm. (b) Representative transmission electron microscopy images of cross sections showing increased size and number of vacuoles and lipid droplets. Scale bar: 5 µm. (c) Representative immunofluorescence images of cell morphology. Cells were stained for F-actin (green), nuclei were stained with Hoechst (blue). Scale bar: 50 μm.
Figure 2Persistent DNA damage in senescent MDA-MB-231 cells. Cells were treated with 100 nM doxorubicin for 24 h, then cultured in a fresh medium and analyzed on subsequent days. (a) Protein level of senescence markers: PARP1 (Poly [ADP-ribose] polymerase 1), p-53, p53 and p21WAF1/CIP1 and elements of DNA damage response: p-ATM, ATM, p-ATR, ATR, γH2AX and Ku70; typical western blot image. (b) Amount of IL-8, IL-6 and VEGF (Vascular Endothelial Growth Factor) secreted by cells measured by ELISA. Bars: mean value, error bars: SEM, n = 3. (c) Representative immunofluorescence images of cells stained for γH2AX (green), 53BP1/Ku70 (red) and nuclei stained with Hoechst (blue). Scale bar: 50 μm. (d) Quantification of γH2AX and 53BP1 foci per cell performed using immunofluorescence microscopy. Each point: mean value ± 0.95 confidence interval, n = 3. Statistical significance (in relation to control): * p < 0.05, ** p < 0.01, *** p < 0.001, between samples: ### p < 0.001.
Figure 3Polyploidy formation and regrowth of senescent MDA-MB-231 cells. Cells were treated with 100 nM doxorubicin for 24 h, then cultured in a fresh medium and analyzed on subsequent days. (a) DNA content of cell nuclei estimated by toluidine blue staining. Scale bar: 50 μm. (b) Percentage of SA-β-gal-positive cells and polyploid ones. Data are calculated as the percentage of the total cell population. Each point: mean value ± 0.95 confidence interval, n = 3. (c) Cell number estimated by trypan blue exclusion. Data are calculated as the percentage of the number of seeded cells. Black square: mean, rectangle: mean ± SD, error bars: mean ± 1.96 * SD, n = 3. Statistical significance (in relation to control): * p < 0.05, ** p < 0.01, *** p < 0.001, between samples: ### p < 0.001.
Figure 4Depolyploidization of a giant senescent MDA-MB-231 cell. Cells were treated with 100 nM doxorubicin for 24 h, then cultured in a fresh medium and analyzed on subsequent days. (a) Intermediate state of asymmetric division. Cells were stained for F-actin (green), nuclei were stained with Hoechst (blue). Scale bar: 50 μm. (b) Multinucleated polyploidy cell with incomplete mitosis, daughter subnuclei remain linked by a series of chromosome bridges (arrow), smaller interphase nuclei marked with a star (*). Toluidine blue staining at pH 4 after shortened acid hydrolysis. Scale bar: 50 μm. (c) Time lapse of asymmetric division of polyploid giant cancer cell on day D1+7, documented with holographic microscope.
Figure 5Autophagic flux resumption in descendants of polyploid/senescent MDA-MB-231 and MCF-7 cells. Cells were treated with 100 nM doxorubicin for one day, then cultured in a fresh medium and analyzed on subsequent days. (a,c) Representative western blots showing autophagy protein levels of p-ULK1 (S757), ULK1, LC3B, LAMP-2 and SQSTM1/p62 in MDA-MB-231 cells (a) and MCF-7 cells (c). (b,d) Quantitative analysis of autophagic index based on LC3B protein levels in untreated and bafilomycin A- or chloroquine-treated MDA-MB-231 cells (b) and MCF-7 cells (d) with representative western blots showing LC3B protein levels. Bars: mean value, error bars: SEM, n = 4. Statistical significance (in relation to control): $ p < 0.051, * p < 0.05, ** p < 0.01. (e) Transient accumulation of autophagic vesicles. TEM images show typical MDA-MB-231cells on the subsequent days following treatment (upper panel) and their magnified parts with autophagic vesicles (red arrows) and lipofuscin particles (red asterisks).
Figure 6Transcription Factor EB (TFEB) translocation to the nucleus in escapers with functional autophagic flux. (a) Representative immunofluorescence images of TFEB (green) protein localization in MDA-MB-231 cells, nuclei stained with Hoechst (blue). Scale bar: 50 μm. (b) Quantitative analysis of the intensity of TFEB fluorescence in nucleus/cytoplasm (IFn/IFc) versus nucleus area in MDA-MB-231 cells. (c,d) Representative western blots showing p-TFEB (S142) and TFEB protein levels in MDA-MB-231 (c) and MCF-7 cells (d).
Figure 7Comparison of parental MDA-MB-231 cells and escapers. Parental cells and escapers were treated with 100 nM doxorubicin for 24 h, then cultured in a fresh medium and analyzed on the 4th day (D1+4). (a) Analysis of population doublings per day. (b) Quantitative analysis of autophagic index based on densitometry of LC3B protein level in untreated and bafilomycin A (BAF)- or chloroquine (CQ)-treated cells. (c) The protein level of Rubicon; densitometry analysis of western blot bands from four independent experiments. (d,e) Percentage of SA-β-gal- and BrdU-positive cells. Data are calculated as the percentage of the total cell population. (f) Amount of IL-8, IL-6 and VEGF secreted by cells on consecutive days after doxorubicin treatment. (g) The average number of γH2AX foci per cell. (h) Representative immunofluorescence images of parental cells and escapers stained for γH2AX (green) and Hoechst (blue). Scale bars: 50 μm. Statistics: bars: mean value, error bars: SEM, each point: mean value ± 0.95 confidence interval, n = 4. Statistical significance (in relation to non-treated (NT) or parental cells): ** p < 0.01, *** p < 0.001, between samples: # p < 0.05, ## p < 0.01, ### p < 0.001.
Primary antibodies used in the study.
| Description | Concentration | Product No. and Manufacturer | |
|---|---|---|---|
| PARP1 | Mouse monoclonal | 1:500 | #556494, BD Bioscences, Franklin Lakes, NJ, USA |
| p53 (DO-1) | Mouse monoclonal | 1:500 | sc-126, Santa Cruz, Dallas, TX, USA |
| p-p53 (S15) | Rabbit polyclonal | 1:500 | #9284, Cell Signaling Technology, Danvers, MA, USA |
| p21 WAF1/CIP1 | Mouse monoclonal | 1:500 | P1484, Sigma-Aldrich, St. Louis, MO, USA |
| ATM (Y170) | Rabbit monoclonal | 1:500 | ab32420, Abcam, Cambridge, UK |
| p-ATM (S1981) | Mouse monoclonal | 1:500 | ab36810, Abcam, Cambridge, UK |
| ATR | Rabbit polyclonal | 1:500 | #2790, Cell Signaling Technology, Danvers, MA, USA |
| p-ATR (S428) | Rabbit polyclonal | 1:500 | #2853, Cell Signaling Technology, Danvers, MA, USA |
| Ku70 (E-5) | Mouse monoclonal | 1:500 | sc-17789, Santa Cruz, Dallas, TX, USA |
| ὙH2AX (S139) | Mouse monoclonal | 1:1000 | ab26350, Abcam, Cambridge, UK |
| ὙH2AX (S139) | Rabbit monoclonal | 1:500 | #9718, Cell Signaling Technology, Danvers, MA, USA |
| 53BP1 | Rabbit polyclonal | 1:500 | NB100, Novus Biologicals, Centennial, CO, USA |
| Ki67 | Rabbit polyclonal | 1:500 | ab15580, Abcam, Cambridge, UK |
| SQSTM1/p62 | Mouse monoclonal | 1:1000 | #610832, BD Bioscences, Franklin Lakes, NJ, USA |
| SQSTM1/p62 | Guinea pig polyclonal | 1:500 | GP62-C, Progen, Heidelberg, Germany |
| LC3B | Rabbit polyclonal | 1:500 | L7543, Sigma-Aldrich, St. Louis, MO, USA |
| ULK1 (D8H5) | Rabbit monoclonal | 1:250 | #8054, Cell Signaling Technology, Danvers, MA, USA |
| p-ULK1 (S757) | Rabbit monoclonal | 1:250 | #14202, Cell Signaling Technology, Danvers, MA, USA |
| m-TOR (7C10) | Rabbit monoclonal | 1:500 | #2983, Cell Signaling Technology, Danvers, MA, USA |
| p-m-TOR (S2448) | Rabbit monoclonal | 1:500 | #5536, Cell Signaling Technology, Danvers, MA, USA |
| p70S6K | Rabbit monoclonal | 1:500 | #2708, Cell Signaling Technology, Danvers, MA, USA |
| p-p70S6K (T389) | Rabbit monoclonal | 1:500 | #9234, Cell Signaling Technology, Danvers, MA, USA |
| p-S6 (S235/236) | Rabbit monoclonal | 1:500 | #4858, Cell Signaling Technology, Danvers, MA, USA |
| 4EBP1 | Rabbit polyclonal | 1:500 | #9452, Cell Signaling Technology, Danvers, MA, USA |
| p-4EBP1 (T37/46) | Rabbit monoclonal | 1:500 | #2855, Cell Signaling Technology, Danvers, MA, USA |
| p-AMPK(T172) | Rabbit monoclonal | 1:500 | #2531, Cell Signaling Technology, Danvers, MA, USA |
| AMPK | Rabbit monoclonal | 1:250 | #2532, Cell Signaling Technology, Danvers, MA, USA |
| p-Akt(S473) | Rabbit monoclonal | 1:2000 | #4060, Cell Signaling Technology, Danvers, MA, USA |
| Akt | Rabbit monoclonal | 1:1000 | #4691, Cell Signaling Technology, Danvers, MA, USA |
| LAMP-2 | Mouse monoclonal | 1:500 | #14-1078-82, eBioscience, Thermo Fisher Scientific, Waltham, MA, USA |
| TFEB | Rabbit polyclonal | 1:250 | #4240, Cell Signaling Technology, Danvers, MA, USA |
| p-TFEB (S142) | Rabbitpolyclonal | 1:500 | ABE-1971, Merck Millipore, Burlington, MA, USA |
| Rubicon | Rabbit monoclonal | 1:500 | #8465, Cell Signaling Technology, Danvers, MA, USA |
| GAPDH | Mouse monoclonal | 1:50,000 | MAB374, Merck Millipore, Burlington, MA, USA |